Clinical trials: Autoimmune
Diabetes Mellitus, Diabetes Mellitus, Type 1
Day and Night Closed-loop in Young People With Type 1 Diabetes
The main study objective is to determine whether 24/7 automated closed-loop glucose control combined with low glucose feature will improve glucose control as measured by HbA1c.
- Conditions
- Diabetes Mellitus, Diabetes Mellitus, Type 1, Glucose Metabolism Disorders, Endocrine System Diseases
- Trial name
- DAN05 (NCT02925299)
- Testing
- FlorenceM (US) and FlorenceX (UK), Insulin pump therapy
- Where
- 11 sites in United States, United Kingdom
- Volunteers
- 133 people
- Sponsor
- Jaeb Center for Health Research
Multiple Sclerosis, Sclerosis
Aerobic Exercise for Remyelination in Multiple Sclerosis
This is a clinical trial to determine the feasibility of a stationary aerobic cycling intervention and explore if aerobic exercise independently promotes remyelination in people with multiple sclerosis (MS).
- Conditions
- Multiple Sclerosis, Sclerosis, Demyelinating Diseases, Autoimmune Diseases of the Nervous System
- Trial name
- NCT04539002
- Testing
- Aerobic exercise, Education Group Control
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Oregon Health and Science University
Autoimmune Pulmonary Alveolar Proteinosis
Clinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
160 subjects with autoimmune pulmonary alveolar proteinosis (aPAP) will be randomized to receive once daily treatment with inhaled molgramostim (MOL) or placebo (PBO) for 48 weeks.
- Trial name
- IMPALA-2 (NCT04544293)
- Testing
- Molgramostim, Molgramostim Open-label
- Where
- 54 sites in United States, Australia and 16 more
- Volunteers
- 164 people
- Sponsor
- Savara Inc.
Warm Autoimmune Hemolytic Anemia (wAIHA)
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ANX005 in Participants With Warm Autoimmune Hemolytic Anemia (wAIHA)
This study will evaluate the safety and tolerability of ANX005 in participants with Warm Autoimmune Hemolytic Anemia (wAIHA).
- Trial name
- NCT04691570
- Testing
- ANX005
- Where
- 4 sites in United States, Australia and 2 more
- Volunteers
- 7 people
- Sponsor
- Annexon, Inc.
Neurological Disorder, Autoimmune Diseases
Disease-Modifying Treatments for Myasthenia Gravis
This study is designed to address the evidence gaps in a real-world setting and help patients with MG choose treatments that are best suited to them.
- Trial name
- PROMISE-MG (NCT03490539)
- Testing
- Mycophenolate Mofetil, Azathioprine
- Where
- 19 sites in United States, Canada
- Volunteers
- 82 people
- Sponsor
- Duke University
Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE)
COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders
This is a randomized, multi-site, adaptive, open-label clinical trial comparing the immune response to different additional doses of COVID-19 vaccine in participants with autoimmune disease requiring IS medications.
- Conditions
- Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Pemphigus Vulgaris, Multiple Sclerosis (MS)
- Trial name
- NCT05000216
- Testing
- Moderna mRNA-1273, BNT162b2, Ad26.COV2.S
- Where
- 29 sites in United States
- Volunteers
- 258 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Arthritis, Rheumatoid
Defining Stress REsilience And Mindfulness Effects in Rheumatoid Arthritis
This clinical trial will test a mindfulness program in individuals with rheumatoid arthritis (RA). The main goals of this pilot study are to: Assess patient satisfaction with a mindfulness course Identify barriers to…
- Trial name
- DREAMER (NCT06276387)
- Testing
- Mindfulness Program
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- University of California, San Francisco
PANDAS, Anxiety Disorder
Trial of Naproxen Sodium for the Treatment of OCD in Children With PANDAS
This project aims to rigorously evaluate a potential treatment for inflammation-related Obsessive-Compulsive Disorder (OCD) symptoms in children.
- Conditions
- PANDAS, Anxiety Disorder, Autoimmune Diseases, Obsessive-Compulsive Disorder
- Trial name
- NCT04015596
- Testing
- Naproxen Sodium
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Massachusetts General Hospital
Sjögren Syndrome
Study of Safety and Efficacy of Multiple Doses of CFZ533 in Two Distinct Populations of Patients With Sjogren's Syndrome
This study was to evaluate the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of multiple doses of CFZ533 (iscalimab) in patients with Sjögren's Syndrome (SjS).
- Trial name
- TWINSS (NCT03905525)
- Testing
- CFZ533
- Where
- 71 sites in United States, Argentina and 21 more
- Volunteers
- 273 people
- Sponsor
- Novartis Pharmaceuticals
Autoimmune Hemolytic Anemia, Chronic Lymphocytic Leukemia
Acalabrutinib for the Treatment of Relapsed or Refractory Autoimmune Hemolytic Anemia in Patients With Chronic Lymphocytic Leukemia
This phase II trial studies the effect of acalabrutinib in treating autoimmune hemolytic anemia that has come back (relapsed) or has not responded to previous treatment (refractory) in patients with chronic lymphocytic leukemia.
- Conditions
- Autoimmune Hemolytic Anemia, Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Warm Antibody Autoimmune Hemolytic Anemia
- Trial name
- NCT04657094
- Testing
- Acalabrutinib
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- City of Hope Medical Center
Immunoglobulin A Nephropathy, Glomerular Disease
Safety and Efficacy Study of VIS649 for IgA Nephropathy
The purpose of this study is to evaluate the efficacy and safety of VIS649 in participants with immunoglobulin A (IgA) Nephropathy (IgAN)
- Conditions
- Immunoglobulin A Nephropathy, Glomerular Disease, IgAN
- Trial name
- NCT04287985
- Testing
- Low Dose-VIS649, Medium Dose-VIS649, High Dose-VIS649
- Where
- 93 sites in United States, Australia and 13 more
- Volunteers
- 155 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Moderate Aplastic Anemia, Unilineage Bone Marrow Failure Disorders
Eltrombopag for Moderate Aplastic Anemia
Background: Moderate aplastic anemia is a blood disease which may require frequent blood and platelet transfusions. Sometimes patients with this disease can be treated with immunosuppressive drugs.
- Trial name
- NCT01328587
- Testing
- Eltrombopag
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Severe Aplastic Anemia
Eltrombopag With Standard Immunosuppression for Severe Aplastic Anemia
Background: Severe aplastic anemia is a rare and serious blood disorder. It happens when the immune system starts to attack the bone marrow cells.
- Trial name
- NCT01623167
- Testing
- Cohort 1: hATG, CsA, EPAG Day 14 to Month 6, Cohort 2: hATG, CsA, EPAG Day 14 to Month 3, Cohort 3: hATG, CsA (dose reduced), EPAG day 1 to month 6
- Where
- United States
- Volunteers
- 207 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Systemic Lupus Erythematosus
Safety and Effectiveness of BENLYSTA (Belimumab) in Systemic Lupus Erythematosus (SLE) Registry
The purpose of this prospective, observational cohort study is to evaluate the incidence of adverse events of special interest (AESI) and effectiveness in participants with active, autoantibody-positive SLE treated with and…
- Trial name
- SABLE (NCT01729455)
- Testing
- Benlysta, Standard of Care (SoC) Therapy
- Where
- 179 sites in United States, Argentina and 11 more
- Volunteers
- 3,138 people
- Sponsor
- GlaxoSmithKline
Lymphoproliferative Disorders, Autoimmune Lymphoproliferative
Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation
Background: Blood stem cells in the bone marrow make all the cells to normally defend a body against disease. Allogeneic blood or marrow transplant is when these stem cells are transferred from one person to another.
- Conditions
- Lymphoproliferative Disorders, Autoimmune Lymphoproliferative, Primary T-cell Immunodeficiency Disorders, Immune System Diseases
- Trial name
- NCT03663933
- Testing
- e-ATG, Immunosuppression Only Conditioning, Reduced Intensity Conditioning
- Where
- 2 sites in United States
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Severe Aplastic Anemia
Early Initiation of Oral Therapy With Cyclosporine and Eltrombopag for Treatment Naive Severe Aplastic Anemia (SAA)
Background: Severe aplastic anemia (SAA) is a rare and serious blood disorder. It causes the immune system to turn against bone marrow cells.
- Trial name
- NCT04304820
- Testing
- Eltrombopag, Cyclosporine, Horse-Anti-thymocyte-Globulin
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Hypoparathyroidism, Hypocalcemia
Comparing Pump With Subcutaneous Injection Delivery of PTH 1-34 in the Management of Chronic Hypoparathyroidism
This randomized crossover study will evaluate the safety, efficacy, and pharmacodynamics of synthetic human PTH 1-34 (PTH) delivered by an insulin pump (omnipod) compared with twice- daily subcutaneous injections.
- Conditions
- Hypoparathyroidism, Hypocalcemia, Autoimmune Polyendocrine Syndrome Type 1, Autosomal Dominant Hypocalcemia Type 1 (ADH1)
- Trial name
- NCT00743782
- Testing
- Synthetic Human Parathyroid Hormone 1-34 pump
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Autoimmune Hepatitis
A Study of Zetomipzomib (KZR-616) in Patients With Autoimmune Hepatitis (PORTOLA)
This was a Phase 2a, multi-center, placebo-controlled study in which patients with autoimmune hepatitis received zetomipzomib or placebo in addition to standard-of-care for 24 weeks; an optional open-label extension period…
- Trial name
- NCT05569759
- Testing
- zetomipzomib, zetomipzomib in open-label extension
- Where
- 24 sites in United States
- Volunteers
- 24 people
- Sponsor
- Kezar Life Sciences, Inc.
Lupus Erythematosus, Systemic
Women Empowered to Live With Lupus Study
The purpose of this research is to examine whether the Chronic Disease Self-management Program (CDSMP) would improve health outcomes and reduce health care use in African American women with systemic lupus erythematosus (SLE).
- Trial name
- WELL (NCT02988661)
- Testing
- Chronic Disease Self-management Program (CDSMP)
- Where
- United States
- Volunteers
- 699 people
- Sponsor
- Emory University
Down Syndrome, Alopecia Areata
Tofacitinib for Immune Skin Conditions in Down Syndrome
People with Down syndrome (DS) display widespread immune dysregulation, including several immune skin conditions. This study hypothesizes that pharmacological inhibition of the increased interferon (IFN) signaling seen in DS is…
- Conditions
- Down Syndrome, Alopecia Areata, Atopic Dermatitis / Eczema, Hidradenitis Suppurativa
- Trial name
- NCT04246372
- Testing
- Tofacitinib
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- University of Colorado, Denver